Phase II Randomized Trial of Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis

OBJECTIVE: To assess the safety, mechanism of action, and preliminary efficacy of rituximab followed by belimumab in the treatment of refractory lupus nephritis (LN). METHODS: In a multicenter, randomized, open‐label clinical trial, 43 patients with recurrent or refractory LN were treated with ritux...

Descripción completa

Detalles Bibliográficos
Autores principales: Atisha‐Fregoso, Yemil, Malkiel, Susan, Harris, Kristina M., Byron, Margie, Ding, Linna, Kanaparthi, Sai, Barry, William T., Gao, Wendy, Ryker, Kristin, Tosta, Patti, Askanase, Anca D., Boackle, Susan A., Chatham, W. Winn, Kamen, Diane L., Karp, David R., Kirou, Kyriakos A., Sam Lim, S., Marder, Bradley, McMahon, Maureen, Parikh, Samir V., Pendergraft, William F., Podoll, Amber S., Saxena, Amit, Wofsy, David, Diamond, Betty, Smilek, Dawn E., Aranow, Cynthia, Dall’Era, Maria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Systemic Lupus Erythematosus
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7839443/
https://www.ncbi.nlm.nih.gov/pubmed/32755035
http://dx.doi.org/10.1002/art.41466

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7839443/
https://www.ncbi.nlm.nih.gov/pubmed/32755035
http://dx.doi.org/10.1002/art.41466

Ejemplares similares